-transparent.png){kind=logo}
At this time, no placebo-controlled studies in the clinical literature compare the efficacy and safety of the most widely prescribed oral inhaled corticosteroids when dosed at their recommended daily doses. This study compared the efficacy and safety of beclomethasone dipropionate (BDP) 336 microg/day administered by metered dose inhaler (MDI) alone, and triamcinolone acetonide (TA) 800 microg/day by MDI with a built-in tube extender in adults with persistent asthma. METHODS This 56-day, randomized, double-blind, double-dummy, placebo-controlled, multicenter trial was conducted in 328 adults with mild to moderately severe asthma (FEV1 50% to 90% of predicted while maintained on inhaled corticosteroids). Patients were seen at a baseline visit and on study days 28 and 56. Efficacy variables included pulmonary function tests, physician and patient assessments of asthma condition, and use of rescue medication. RESULTS Statistically significant improvements from baseline in most efficacy measures were demonstrated for both active treatments versus placebo, and with the following exception were the same between active treatments: mean increase in FEV1 in the beclomethasone dipropionate group was statistically significantly greater than in the triamcinolone acetonide group on day 28. Throughout the study, BDP was statistically superior to TA with respect to mean change from baseline in total asthma symptom scores and for 3 of 8 weeks in reducing the mean average weekly use of rescue albuterol (the two active treatments were comparable for this variable at all other time points). Beclomethasone dipropionate and TA were comparable in safety. CONCLUSIONS In adult patients with mild to moderately severe persistent asthma, treatment with BDP consistently conferred greater improvement from baseline in mean FEV1 than TA. This difference achieved statistical significance after 28 days of therapy but was not maintained to endpoint. Decreases in overall asthma symptom scores and in the use of rescue albuterol were statistically significantly greater for the BDP group compared with the TA group. Based on these findings, we conclude that BDP is at least as effective as TA in the treatment of persistent asthma in adults, and judged by some measures, may be superior.
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
March 1976,
Canadian family physician Medecin de famille canadien,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
October 1992,
Presse medicale (Paris, France : 1983),
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
June 1985,
Journal of speech and hearing research,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
May 1987,
Annals of internal medicine,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
January 1986,
The Journal of asthma : official journal of the Association for the Care of Asthma,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
January 1975,
Postgraduate medical journal,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
May 1996,
American journal of respiratory and critical care medicine,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
May 1999,
Respiratory medicine,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
January 1991,
Pneumoftiziologia : revista Societatii Romane de Pneumoftiziologie,
E Bronsky, and
P Korenblat, and
A G Harris, and
R Chen
April 1987,
British journal of diseases of the chest,
